The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review
Open accessAbstract
Hidradenitis suppurativa (HS) is a chronic autoinflammatory follicular disease, affecting body areas that are rich in apocrine glands. Moderate-to-severe HS may severely impair patients' quality of life also because the available therapies are often unsatisfactory. Several lines of evidence suggest that inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-17 play a pivotal role in the physiopathology of HS. TNF-α inhibitors have long been used with benefit in moderate-severe forms of HS. However, several monoclonal antibodies against IL-17 isoforms are currently being investigated for HS. We report the case of a 50-year-old man with long-standing HS and concomitant palmo-plantar psoriasis treated with brodalumab after failure of various TNF-α inhibitors. The HS lesions and the patient's quality of life improved steadily over time until week-136. Interestingly, the clinical benefit was confirmed by radiological improvement with MRI evaluation. Our case report demonstrates the long-term efficacy and safety of brodalumab in HS encouraging the use of drugs to inhibit the T helper-type 17 immune axis, especially in cases of HS refractory to therapy with TNF-α inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In advanced diseases with tunnel formation and fibrosis, surgical management remains essential, often combined with medical therapy to control inflammation and prevent recurrence [40,44,45,46,47].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [47]
Citations
Cites
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F. A., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 813
van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10254.x · Cited by 473
Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00022-3 · Cited by 343
Witte‐Händel, E., Wolk, K., Tsaousi, A., Irmer, M. L., Mößner, R., Shomroni, O., Lingner, T., Witte, K., Kunkel, D., Salinas, G., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.018 · Cited by 251
Matusiak, Ł., Szczęch, J., Bieniek, A., Nowicka‐Suszko, D., & Szepietowski, J. C. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.042 · Cited by 185
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Glatt, S., Jemec, G. B. E., Forman, S. B., Sayed, C. J., Schmieder, G. J., Weisman, J. D., Rolleri, R., Seegobin, S., Baeten, D., Ionescu, L., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.2905 · Cited by 182
Frew, J. W., Navrazhina, K., Grand, D., Sullivan-Whalen, M. M., Gilleaudeau, P., Garcet, S., Ungar, J. P., & Krueger, J. G. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.05.007 · Cited by 116
Frew, J. W., Marzano, A. V., Wolk, K., Join‐Lambert, O., Alavi, A., Lowes, M. A., & Piguet, V. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.019 · Cited by 71
Navrazhina, K., Frew, J. W., Grand, D., Williams, S. C., Hur, H. B., Gonzalez, J., Garcet, S., & Krueger, J. G. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21060 · Cited by 53
Weekly administration of brodalumab in hidradenitis suppurativa: an open‐label cohort study
Frew, J. W., Navrazhina, K., Sullivan-Whalen, M. M., Gilleaudeau, P., Garcet, S., & Krueger, J. G. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19478 · Cited by 52
Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review
Kashetsky, N., Mufti, A., Alabdulrazzaq, S., Lytvyn, Y., Sachdeva, M., Rahat, A., & Yeung, J. (2021) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754211035667 · Cited by 37
Arenbergerová, M., Arenberger, P., Marques, E., et al. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14792 · Cited by 26
Kearney, N., Hughes, R., & Kirby, B. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad130 · Cited by 21
Yoshida, Y., Oyama, N., Iino, S., Shimizu, C., & Hasegawa, M. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15807 · Cited by 20
Tampouratzi, E., Kanni, T., Katsantonis, J., et al. (2020) · F1000Research · doi:10.12688/f1000research.21216.2 · Cited by 12
Cited by
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1
“In advanced diseases with tunnel formation and fibrosis, surgical management remains essential, often combined with medical therapy to control inflammation and prevent recurrence [40,44–47].”
Metadata
- Authors
- Vagnozzi, E., Bruni, M., Esposito, M., & Fargnoli, M. C.
- Affiliations
- University of L'Aquila (IT)
- San Salvatore Hospital (IT)
- Corresponding author
- Esposito, Maria
- Venue
- Journal of Dermatological Treatment
- Publisher
- Informa UK Limited
- Published
- 2023-10-16
- Volume
- 34
- Issue
- 1
- Pages
- 2270091-2270091
- ISSN
- 0954-6634 (ISSN-L)
- 1471-1753
- OpenAlex
- W4387661741
- Cited by
- 11
- References
- 15
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Dermatological Treatment (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Dermatology › Hidradenitis Suppurativa and Treatments
- Health Sciences › Medicine › Dermatology › Autoimmune and Inflammatory Disorders
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- hidradenitis suppurativa, brodalumab, IL-17 inhibition, TNF-alpha inhibitors, MRI response assessment, quality of life, monoclonal antibodies
- MeSH terms
- Humans, Male, Middle Aged, Quality of Life, Tumor Necrosis Factor-alpha, Hidradenitis Suppurativa, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
